Astrazeneca PLC ORD SHS $0.25
Astrazeneca PLC ORD SHS $0.25/ GB0009895292 /
AZN
|
1/10/2025 9:23:51 AM
|
Chg.
-10.0000
|
Volume |
Bid9:23:51 AM |
Ask9:23:52 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
10,978.0000GBX
|
-0.09%
|
43,419
Turnover(GBP): 4.76 mill. |
10,978.0000Bid Size: 284 |
10,982.0000Ask Size: 485 |
167.38 bill.GBP |
- |
- |
Business description
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Management board & Supervisory board
| CEO |
| Pascal Soriot |
| Management board |
| Aradhana Sarin, Pam Cheng, Ruud Dobber, Marc Dunoyer, David Fredrickson, Susan Galbraith, Jeff Pott, Iskra Reic, Leon Wang, Sharon Barr |
| Supervisory board |
| Michel Demaré, Pascal Soriot, Aradhana Sarin, Philip Broadley, Euan Ashley, Deborah DiSanzo, Diana Layfield, Sheri McCoy, Tony Mok, Nazneen Rahman, Andreas Rummelt, Marcus Wallenberg, Anna Manz |